Xenetic Biosciences Inc. Common Stock (XBIO)
Stock · NASDAQ · Health Care
$1.99as of 10/16/2026
Price chart
Active signals
XBIO Signal Track Record
How signals performed across all stocks →What XBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| 200-Day Moving Average TouchActive now | 28 | +0.3% | 50% | July 15, 2026 |
| Bollinger Band Breakout | 25 | -6.2% | 48% | September 3, 2026 |
| Volume Spike | 23 | +2.1% | 52% | September 3, 2026 |
| Bollinger Band Breakdown | 20 | +1.9% | 65% | September 16, 2026 |
| Any 20-session window (baseline) | -0.7% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carci…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2
- Website
- www.xeneticbio.com/
Fundamentals
- 1-day range
- $1.92$2
- Market cap
- $6.53M
- P/E (trailing)
- —
- P/E (forward)
- -3.02
- EPS (trailing)
- $-1.20
- Dividend yield
- —
- Beta
- 2.36
- Avg. volume
- 89.2K
- Dividend pay date
- June 25, 2019
How Xenetic Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Xenetic Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XBIOXenetic Biosciences Inc. Common Stock$1.99▼ 1.00%Market cap $6.53MP/E —$1.87$5.28
- ALZNAlzamend Neuro Inc. Common Stock$1.3▲ 1.56%Market cap $6.61MP/E —$0.84$2.68
- IMNNImunon Inc. Common Stock$1.02▼ 3.77%Market cap $6.64MP/E —$0.96$5.29
- CVKDCadrenal Therapeutics Inc. Common Stock$1.09▲ 12.37%Market cap $6.67MP/E —$0.8163$14.35
- ENVBEnveric Biosciences Inc. Common Stock$1.38▼ 0.72%Market cap $6.28MP/E —$1.17$13.25
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.1▼ 5.98%Market cap $6.27MP/E —$1.15$7.87
- FBLGFibroBiologics Inc. Common Stock$0.971▼ 2.90%Market cap $6.79MP/E —$0.62$9.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $1.99 | ▼ 1.00% | $1.87$5.28 |
| ALZN Alzamend Neuro Inc. Common Stock | $6.61M | — | $1.3 | ▲ 1.56% | $0.84$2.68 |
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.02 | ▼ 3.77% | $0.96$5.29 |
| CVKD Cadrenal Therapeutics Inc. Common Stock | $6.67M | — | $1.09 | ▲ 12.37% | $0.8163$14.35 |
| ENVB Enveric Biosciences Inc. Common Stock | $6.28M | — | $1.38 | ▼ 0.72% | $1.17$13.25 |
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.27M | — | $1.1 | ▼ 5.98% | $1.15$7.87 |
| FBLG FibroBiologics Inc. Common Stock | $6.79M | — | $0.971 | ▼ 2.90% | $0.62$9.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israelbenzinga · 10/15/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 10/5/2026
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · 9/22/2026
- Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% StakeYahoo · 9/16/2026
- Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus AcquisitionYahoo · 9/16/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/16/2026
- Crude Oil Down Over 3%; US Business Inventories Surge In JulyBenzinga · 9/16/2026
- Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks TranscriptSeekingAlpha · 9/16/2026
- Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting TherapeuticsYahoo · 9/16/2026
Insider Activity
Insider Actions →- James F. Parslow · April 21, 2026 · Grant100.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 169.1K
- Total value held
- $446.0K
- Institutional holders
- 6
- Unknown137.4K
- Unknown21.4K
- Unknown6.7K
- Unknown2.7K
- Unknown806
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Xenetic Biosciences (XBIO) Moves in Monday Pre-Market
Xenetic Biosciences (XBIO) was one of 12 health‑care stocks that moved in the Monday pre‑market session. The early trading activity suggests increased investor interest ahead of the regular market open. XBIO’s price action in pre‑market was part of a broader shift among health‑care names that day.
Xenetic Biosciences (XBIO) Moves in Monday Pre-Market. Xenetic Biosciences (XBIO) was one of 12 health‑care stocks that moved in the Monday pre‑market session. The early trading activity suggests increased investor interest ahead of the regular market open. XBIO’s price action in pre‑market was part of a broader shift among health‑care names that day.